XML 23 R17.htm IDEA: XBRL DOCUMENT v3.25.3
Related Party
 9 Months Ended
Sep. 30, 2025
Related Party Transactions [Abstract]  
Related Party
9.
Related Party

In May 2024, the Company entered into an agreement with the Friedreich’s Ataxia Research Alliance (“FARA”) to join the TRACK-FA Neuroimaging Consortium that includes pharmaceutical, biotechnology, academic and clinical partners. The consortium is conducting a natural history study designed to establish disease-specific neuroimaging biomarkers to track disease progression in the brain and spinal cord and provide a basis for utilizing these biomarkers in clinical trials. As an industry partner, the Company is helping to fund the study and contribute to the study design, research activities, and analysis. The Company has access to all study data for use in its regulatory filings, as appropriate. During the twelve months ended December 31, 2024, the Company incurred $0.9 million of costs related to the Track-FA program and will fund future costs going forward. One of the Company’s Directors is also a director of FARA. During the nine months ended September 30, 2025, the Company incurred less than $0.1 million of costs related to the Track-FA program.

Additionally, during three and nine months ended September 30, 2025, the Company sponsored patient and caregiver awareness events held by FARA for a cumulative of less than $0.1 million and $0.1 million, respectively. During the twelve months ended December 31, 2024, the Company sponsored patient and caregiver awareness events held by FARA for a cumulative $0.1 million.